To evaluate the efficacy, safety and patients' preference of different treatment modalities of ED in men with SCI. Sixty SCI men with ED were included in the study. They were divided into three groups. Group A received sildenafil, group B received intracorporal injection (ICI) and were then shifted to sildenafil and group C used vacuum constriction devices (VCD) and were then shifted to sildenafil. Erection was evaluated before and after each treatment. Ninety percent of patients reported improvement of erection after sildenafil and ICI treatment according to IIEF-EF and only 70% of patients reported improvement in erection with VCD. However, 14 patients reported that they preferred sildenafil due to the easier route of administration. In men with SCI, sildenafil is the most effective treatment and is widely accepted. ICI, VCD therapy in SCI patients should be used according to patient's preference and choice.
Introduction
In recent years, as a result of the reduction of mortality rates in patients with spinal cord injury (SCI), the treatment emphasis has shifted from ensuring survival to enhancing quality of life. 1 Erectile dysfunction (ED) is a common complication in men with SCI. 2 However, many studies have shown that as many as 95% of patients with upper motor neuron lesions could develop an erection with stimulation. Also, patients below the age of 30 years appear to be more likely to record erectile capabilities but the quality of erection might not be satisfactory for the patient and might not be sufficient for intercourse. In the literature, the percentage of successful intercourse without treatment in men with SCI ranged from 53 to 75% according to the level and completeness of injury. [3] [4] [5] Treatment options for ED in patients with SCI included intracavernosal injection of vasoactive substances (ICI), vacuum constriction devices (VCD) and surgical implantation of penile prosthesis. 3, [6] [7] [8] Although these therapies have been reported to address the needs of patients with SCI who have ED, they are rarely ideal; for example, ICI although the most used treatment option, has been associated with a dropout rate of more than 50%. 3 Patients also tend to reject the use of external VCD because they want to have more naturally occurring erections within the context of sexual stimulation by a partner. 8 Derry et al., 2 however, reported that sildenafil is efficacious and well tolerated by SCI patients.
The aim of the present study was to evaluate the efficacy, safety and patients' preference of different treatment modalities of ED in men with SCI.
Patients and methods
The study was carried out on 60 spinal cord injured men complaining of weak erection. The study was conducted in the university hospital and was funded totally by Andrology Department. Inclusion criteria included marriage with stable sexual relation with a female partner for at least 6 months before the study to insure adequate sexual excitation and orientation of the patient to the sexual act. Also, duration of injury should be at least 6 months.
Exclusion criteria included any possible organic or psychogenic aetiology for ED including genital anatomical abnormalities (penile curvature or severe hypospadius), major hematological, renal or hepatic abnormalities, diabetes mellitus, history of stroke or myocardial infarction or any significant cardiovascular disease within the last 6 months. Men with history of ED before SCI were excluded. Also, men with life style factors, such as smoking, alcohol or drug abuse, that may affect erectile function were excluded.
All participants were subjected to full history taking, general and local genital examination and neurological assessment (done by a professional neurologist to assess stability of the case, the level and completeness of injury). Hormonal profile was done for all subjects, before and after treatment, including prolactin and testosterone levels using immulite system. Samples were taken at 1000 h and all analyses were done in a single laboratory. The reference ranges for normal values were 2.5-10 ng/ml for testosterone and 3-17 ng/dl for prolactin.
Multiple questionnaires were used for evaluation of subjects included in the study. Sexual Health Inventory for Men (SHIM) questionnaire was filled up at the beginning of the study. If the score was 21 or less, this would be suggestive of the presence of the ED. The International Index of Erectile Function (IIEF), which is a brief, reliable, multidimensional, self-administered measure for the clinical assessment of ED and treatment outcomes, was filled up before and after treatment. The international index of erectile function: erectile function domain score (IIEF-EF) was also used to assure the diagnosis of ED and also to evaluate the severity of ED and the response for treatment. Global efficacy assessment questions (GAQ), which measures the efficacy of the treatment on ED, was filled up for all patients after any type of treatment.
Patients were randomized into three groups (A, B and C). Each group included 20 patients. All patients were asked to stop any medication for ED for 1 month before the study. Patients in group A were given sildenafil only for 1 month as required approximately 1 h before planned sexual activity but not more than one dose per day. Sildenafil 50 mg was used as the starting dose for all patients. The sildenafil dose of 25 mg was used in patients with very good response to sildenafil 50 mg or in patients who could not tolerate the side effects of larger doses. As sildenafil 25 mg is not available in our country we divided the 50 mg tablet. Depending on the efficacy and tolerability, the dose could be increased to maximum of two tablets (100 mg). Patients in group B were given intracorporal injection (10 mg/ml prostaglandin E 1 or 0.5 ml trimix) for 1 month and were then shifted to sildenafil for 1 month. Patients in group C used VCD for 1 month and were then shifted to sildenafil for 1 month.
The study design and all the procedures included in the work were approved by the ethical committee of the Andrology Department. A written consent was provided and explained to all patients before any procedure.
Statistical analysis
Descriptive statistics (arithmetic mean and s.d.) were used for summary of quantitative data. Analytical statistics included paired sample t-test, which was used in comparing means before and after treatment interventions and one-way ANOVA, which was used to test the equality of means between student groups. Table 1 shows demographic data of patients in the three groups studied. No significant difference was found between the groups regarding these parameters.
Results

Sexual history
The patients reported a frequency of intercourse ranging from twice per week to once per month. Only six (10%) patients reported having the ability of psychogenic erection while the other 54 (90%) patients reported having only reflexogenic erection. All patients reported that they were not satisfied by the quality of erection although it may be sufficient to complete the sexual intercourse. Twenty-eight patients complained that the erection was not sustained for a period of time enough for satisfactory intercourse. Twenty-nine patients complained that the rigidity of erection was not satisfactory. Twenty- one patients stated that although they could attain reflexogenic erection, however it could not be attained during every sexual intercourse. Table 2 shows the injury level of patients included.
Neurological assessment
The causes of injury in these patients varied widely but were mainly due to car accident or gun shot. All injuries were of the upper motor neuron type.
Eleven patients had incomplete SCI while the other 49 had complete SCI. All patients were neurologically stable.
Sexual health inventory for men questionnaire Pretreatment SHIM mean score ranged from 5 to 18 in group A, from 5 to 15 in group B and from 8 to 18 in group C.
The international index of erectile function Table 3 shows the range and the mean scores of IIEF in the study groups before and after different treatment modalities. There was highly significant response for sexual function in all groups after sildenafil and after ICI in group B and only significant response after VCD in group C.
The international index of erectile function-erectile function domain score Table 4 shows the response of all the patients before and after different treatment modalities. The improvement of erection was 90% in all groups after sildenafil therapy, 90% after ICI therapy in group B and 70% after VCD therapy in group C. The table also shows the range and the mean scores of IIEF-EF in the study groups before and after different treatment modalities. There was highly significant improvement in erection in all groups after treatment with sildenafil and after ICI therapy in group B. There was significant improvement in erection after VCD therapy in group C.
Global efficacy assessment questionnaire Table 5 shows the number and percentage of improvement after different treatment modalities using GAQ. Improvement of erection reached 100% in all groups after sildenafil therapy, after ICI in group B and after VCD in group C but ability to penetration reached 90% after sildenafil therapy in all groups, ICI in group B and 70% after VCD in group C. Table 6 shows the range hormonal profile before and after treatment with sildenafil in all groups. There was significant increase in testosterone level after treatment with sildenafil in all groups.
Hormonal profile
Dose and side effects of sildenafil Table 7 shows side effects of sildenafil. The main side effects after ICI were the bruising and swelling found in 20% of cases and prolonged erection in 10% of patients. The main side effects after VCD were lack of spontaneity, uncomfortable erections and 'cold penis' for partner. No serious drop of blood pressure was recorded in any of our patients.
Patient's preference to the type of treatment
Patients of group B reported that ICI resulted in more rigid erection than sildenafil. However, 14 patients reported that they preferred sildenafil due to the easier route of administration while the other six patients preferred ICI. Seventy percent of patients in group C reported that VCD produced erection sufficient for intromission; however, all patients were not satisfied by the method and preferred sildenafil or ICI.
No correlation could be found between patients' preference of type of ED treatment and any other factor including patient's age, injury duration, level or completeness of injury.
Level of the lesion and response to treatment
No correlation could be found between the level of injury and response of the patients to the three modalities of treatment using IIEF and IIEF-EF.
Discussion
Traumatic SCI is a common occurrence throughout the world with estimated 15 000 new cases occurring annually in the United States. 9 ED is a common complication in men with SCI. However, it is reported that 80-95% of these patients can achieve some type of erection: reflexogenic, psychogenic or mixed. 3, 10 Treatment options for ED in patients with SCI include intracavernosal injection of vasoactive substances, VCD and surgical implantation of penile prothesis. 3, 6, 8 The American Urological Association Panel on the treatment of organic ED stated that the ultimate goal is a therapy that is reliable, has minimal side effects and is simple to use. 9 Sildenafil appears to meet these specifications.
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The present study was a prospective open-label comparative study including 60 patients with weak erection, due to spinal cord injury, according to SHIM score. All patients received sildenafil as a single treatment, while 20 patients out of them received ICI before sildenafil and another 20 patients used VCD before sildenafil therapy.
Various studies were conducted to evaluate the effect of sildenafil in treatment of ED in men with SCI. The first one was a double-blind, placebocontrolled, randomized study and reported improvement in erection and sexual function after 4 weeks of treatment in 75% on sildenafil 50 mg and 7% on placebo. 2 In another prospective study, 80% of patients reported that sildenafil improved their ability to have intercourse whereas there was only a 10% response in placebo group. 12 Another study reported that 93% of patients have a positive response to sildenafil and reached a penile rigidity sufficient to permit sexual intercourse and only 37% of patients required higher doses of 75-100 mg. 13 In the present study, 90% of patients reported improvement of erection after sildenafil intake according to IIEF-EF with highly significant improvement of sexual function according to IIEF and efficacy up to 100% according to GAQ. Sildenafil leads to erection sufficient for intercourse in 90% of patients in all three groups.
In year 1983, Brindly 14 obtained full erection in two of three men with SCI using an intracavernosal injection of phentolamine. Since that time, several reports have been published on the use of papaverine, or a combination of papaverine and phentalamine and more recently prostaglandin E 1 in men with SCI. 4, 15, 16 It should be noted that the dose for SCI was significantly lower than that needed for other etiologies of ED. In the present study, after ICI therapy, 90% of patients had normal erections according to IIEF-EF score and highly significant Reference value of testosterone ¼ 2.5-10 ng/ml. Prolactin ¼ 3-17 ng/ml. Vacuum constriction device has proved popular in spinal cord injured patients. An early report on 20 SCI men with ED using VCD stated that at 3 months, 93% of the men reported rigidity sufficient for vaginal penetration. These numbers decreased somewhat at the 6 month to only 41% with premature loss of rigidity during intercourse the most commonly reported complaint. 17 In another study only 23% of patients asked for a prescription after a 2-week trial and only 53% of these reported complete or reasonable satisfaction. 18 In the present study after VCD therapy, 70% of patients had normal erection regarding IIEF-EF score with significant improvement in sexual function according to IIEF score. This wide range of variation in response of patients might be related to the acceptability by the patient and his partner.
The most commonly reported adverse events of sildenafil in dose range of 25-100 mg were the following, mild and transient headache (15.8%), flushing (10.5%), dyspepsia (6.5%), nasal congestion (4.2%) and hypotension (2.7%). 19 In the present study, the side effects of sildenafil therapy in all groups after the first week with a range dose of 50 mg were: headache (41.7%), flushing (8.3%), dyspepsia (8.3%), nasal congestion (3.3%) and hypotension (1.7%). In the last week with a range dose of 50-100 mg the adverse events were: headache (10%), flushing (5%), dyspepsia (6.7%), hypotension (15%) and nasal congestion (21.7%). The main side effects after ICI were bruising and swelling (20%) and prolonged erection (10%) of patients. The main reported side effects after VCD were potential risk of ischemic injury and over-vigorous suction causing subcutaneous hemorrhage. 20 In the present study, main side effects after VCD were lack of spontaneity, uncomfortable erections and 'cold penis' for partner.
The patients' preference to the type of treatment was assessed in the present work. Seventy percent of patients in group B who where initially treated with ICI stated that they preferred sildenafil due to the easier route of administration. All patients in group C reported that were not satisfied with the vacuum constricting device although it may result in good erection sufficient for intromission. This was attributed to the difficulty in using the method and loss of spontaneity during intercourse. Moreover, the relatively short time available for intercourse as the constricting ring should be removed after 30 min, and due to their SCI they usually need more time to complete the sexual intercourse.
In the present study, an interesting finding was observed, that there was a significant increase in testosterone level after treatment with sildenafil in all groups although the increase was within the normal range. This finding was also reported by Carosa and coworkers 21, 22 in 74 patients with ED receiving sildenafil and tadalafil. They explained this finding by the fact that lack of sexual activity due to ED decreases testosterone levels through a central effect on the hypothalamic-pituitary axis. Phosphodiesterase inhibitors lead to improvement of erectile function leading subsequently to reversal of this endocrine pattern.
Conclusions
In men with SCI, sildenafil is the most preferable treatment and is widely accepted. However, ICI and VCD therapy in SCI patients should be used according to patient's preference and choice, such as whether the patient is unsuitable to the oral sildenafil, whether there is inadequate response to sildenafil and whether there are side effects from use of sildenafil.
